Denali Therapeutics Inc

XNAS:DNLI

25.83

-0.15 (-0.58%)

7:38:21 PM EDT: $25.80 -0.03 (-0.12%)

Market Cap (Intraday)	4.08B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$2.17 Million
Adjusted EPS	-$0.71

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Denali Therapeutics Inc Stock, XNAS:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080

United States of America

Phone: +1.615.866.8548

Number of Employees: 422

http://www.denalitherapeutics.com

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.